Type I Insulin-Like growth factor receptor

Research output: Chapter in Book/Report/Conference proceedingChapter


The insulin-like growth factor (IGF) system has been implicated in many times of cancer. Upon ligand binding, the type I IGF receptor (IGF1R) transmembrane tyrosine kinase receptor is activated and serves to activate multiple downstream signaling targets. Multiple drugs have been developed to disrupt the function of this receptor, but to date the clinical trial results have been disappointing.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Number of pages7
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
StatePublished - Jan 1 2017

Bibliographical note

Publisher Copyright:
© Springer Science+Business Media New York 2017. All rights reserved.


  • Breast cancer
  • Clinical trials
  • Ewing's sarcoma
  • Fibroblast cells
  • Functional IGF1R
  • IGF-II
  • Monoclonal antibodies
  • Multianalyte molecular techniques
  • TKIs
  • Type I insulin-like growth factor receptor (IGF1R)
  • Tyrosine kinase inhibitors (TKIs)
  • mRNA expression and protein levels
  • ras/raf/MEK/MAPK and PI3K/Akt/mTORC1 signaling cascades


Dive into the research topics of 'Type I Insulin-Like growth factor receptor'. Together they form a unique fingerprint.

Cite this